Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study
Summary: Background: In the global REACH-2 study, ramucirumab significantly improved overall survival (OS) compared with placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). REACH-2 China study aimed to evaluate the efficacy and safety of ramuciruma...
Main Authors: | Guoliang Shao, Yuxian Bai, Xianglin Yuan, Xiaomin Chen, Shanzhi Gu, Kangsheng Gu, Chunhong Hu, Houjie Liang, Yabing Guo, Jufeng Wang, Chia-Jui Yen, Victor Ho-Fun Lee, Chunxiao Wang, Ryan C. Widau, Wanli Zhang, Junjun Liu, Qiang Zhang, Shukui Qin |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | EClinicalMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537022004096 |
Similar Items
-
Delayed esophageal anastomotic complication and ramucirumab therapy: A case report
by: Robert H. Roth, et al.
Published: (2023-10-01) -
Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
by: Hamid Rezvani, et al.
Published: (2022-01-01) -
Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
by: Kosuke Hamai, et al.
Published: (2023-04-01) -
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
by: Naoya Kanogawa, et al.
Published: (2023-03-01) -
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study
by: Yutaka Yasui, et al.
Published: (2022-06-01)